Glucagon-like Peptide 1, total

Glucagon-like Peptide 1 (GLP-1) consists of two biologically active forms, GLP-1 (7-37) and GLP-1 (7-36). GLP-1 has several physiological properties that may make it useful as a potential treatment for diabetes mellitus. GLP-1 increases insulin secretion and decreases glucagon secretion from the pancreas. Other functions include the inhibition of acid secretion and gastric emptying in the stomach, an increase in beta cell mass and insulin gene expression and a decrease in food intake due to increased satiety. Once GLP-1 enters the blood stream it has a half life of less than two minutes due to rapid degradation by the enzyme DPP-1V.

Swiss-Prot Accession Number: P01275